| |
ADC overall cohort
|
ADC neuroendocrine marker positive
|
ADC neuroendocrine marker negative
|
p value
|
|---|
|
n
|
%
|
n
|
%
|
n
|
%
| |
|---|
|
Patients
|
627
|
100
|
110
|
100
|
517
|
100
| |
|
Gender
|
|
Male
|
365
|
58
|
67
|
61
|
298
|
58
|
0.528
|
|
Female
|
262
|
42
|
43
|
39
|
219
|
42
| |
|
Age, median y (range)
|
63 (30–89)
|
63 (41–84)
|
63 (30–89)
|
0.373
|
|
TNM
|
|
pT
|
|
pT1
|
127
|
20
|
25
|
23
|
102
|
20
|
0.535
|
|
pT2
|
388
|
62
|
63
|
57
|
325
|
63
| |
|
pT3
|
94
|
15
|
17
|
15
|
77
|
15
| |
|
pT4
|
18
|
3
|
5
|
5
|
13
|
3
| |
|
pN
|
|
pN0
|
314
|
50
|
63
|
57
|
251
|
49
|
0.068a
|
|
pN1
|
94
|
15
|
14
|
13
|
80
|
15
| |
|
pN2
|
192
|
31
|
28
|
25
|
164
|
32
| |
|
pN3
|
5
|
1
|
0
|
0
|
5
|
1
| |
|
pNX
|
22
|
4
|
5
|
5
|
17
|
3
| |
|
pM
|
|
pM1
|
26
|
4
|
2
|
2
|
24
|
5
| |
|
pMX
|
601
|
96
|
108
|
98
|
493
|
95
| |
|
Stage
|
|
I
|
254
|
41
|
46
|
42
|
208
|
40
|
0.153b
|
|
II
|
130
|
21
|
29
|
26
|
101
|
20
| |
|
III
|
217
|
35
|
33
|
30
|
184
|
36
| |
|
IV
|
26
|
4
|
2
|
2
|
24
|
5
| |
|
Genetic aberrations
|
|
KRAS
|
147c
|
36
|
29d
|
36
|
118e
|
36
|
0.732f
|
|
EGFR
|
64c
|
16
|
10d
|
8
|
52
|
16
| |
|
BRAF
|
14c
|
3
|
2d
|
3
|
12
|
4
| |
|
ROS1
|
5c
|
1
|
1d
|
1
|
4
|
1
| |
|
ALK
|
5c
|
1
|
0d
|
0
|
5
|
2
| |
- ADC adenocarcinoma, M metastases, N nodal stage, T tumor size, y year
- apN0 versus pN1/pN2/pN3; pNX not included
- bstage I versus II versus III/IV
- cavailable for 405 cases
- davailable for 80 cases
- eavailable for 327 cases
- fKRAS versus EGFR versus BRAF/ROS1/ALK
